PCOS & Fertility
For women living with polycystic ovary syndrome (PCOS), trying to conceive can come with unexpected challenges.
Irregular ovulation, hormonal imbalances and insulin resistance can all influence reproductive health. But new research is revealing just how closely metabolic health and fertility may be connected.
Two studies published in October 2026 are bringing fresh attention to this relationship, including the potential role of medications originally developed for diabetes and weight management.
A New Discovery in PCOS and Fertility
A study published on 15 October 2026 in the European Journal of Obstetrics & Gynecology and Reproductive Biology investigated whether GLP-1 receptor agonists could improve pregnancy outcomes in women with PCOS.
These medications, which include treatments such as liraglutide and semaglutide, are known for their effects on appetite, blood glucose regulation and weight management.
Researchers analysed three randomised clinical trials involving 252 participants.
The findings suggested that GLP-1-based treatment may increase the likelihood of natural conception compared with metformin alone.
However, the researchers did not find a statistically significant improvement in overall pregnancy rates or IVF pregnancy outcomes.
Although encouraging, the evidence remains limited, and larger clinical trials are needed before firm conclusions can be drawn.
Why Is Metabolic Health Important for Fertility?
PCOS is more than a condition affecting the ovaries.
It is a complex hormonal and metabolic disorder that can influence multiple systems throughout the body.
One important factor is insulin resistance, which occurs when the body’s cells become less responsive to insulin.
In women with PCOS, elevated insulin levels can contribute to increased androgen production and disruption of normal ovulation.
This may make conception more difficult.
Understanding and managing metabolic health can therefore be an important part of fertility care.
A Second Study Offers Further Insight
Another study, published on 10 October 2026 in The Journal of Clinical Endocrinology & Metabolism, examined health outcomes among women with PCOS who had received GLP-1-based treatment before pregnancy.
The researchers compared 48,126 women receiving GLP-1 or related treatments with an equally sized matched group receiving metformin.
They found an association between treatment before conception and a lower risk of several adverse pregnancy outcomes.
However, because this was an observational analysis, it cannot establish that the medications directly caused the improvements.
The findings also do not demonstrate that these medications are safe to use during pregnancy.
Together, these studies highlight the importance of metabolic health before conception.
What Does This Mean for Women Planning a Pregnancy?
The latest findings suggest that future fertility care may increasingly consider metabolic and hormonal health together.
For women with PCOS, preparing for pregnancy may involve:
- Understanding menstrual cycles and ovulation patterns.
- Assessing blood glucose regulation and insulin resistance where appropriate.
- Maintaining balanced nutrition and regular physical activity.
- Discussing individual fertility concerns with a healthcare professional.
- Reviewing medications before attempting conception.
GLP-1 medications are not established fertility treatments, and women planning pregnancy should seek medical advice about when to discontinue them.
The broader message is that reproductive health is influenced by many interconnected biological processes.
SHAWKEA: A Science-Led Approach to Reproductive Wellbeing
At SHAWKEA, we believe that understanding reproductive health begins with recognising the complex relationship between nutrition, metabolism and the body’s natural biological processes.
Our interest in women’s reproductive wellbeing extends beyond any single aspect of fertility.
Emerging research into PCOS, insulin resistance and reproductive outcomes reinforces the importance of continued scientific investigation.
Through our focus on botanical ingredients and nutritional wellbeing, SHAWKEA aims to encourage informed conversations about reproductive health and the importance of evidence-based approaches.
Although the studies discussed did not investigate SHAWKEA T-1, they contribute to the wider scientific understanding of the factors that influence fertility.
Looking Towards the Future
As fertility science advances, researchers are increasingly exploring the connections between hormonal balance, metabolic function and reproductive outcomes.
The latest October 2026 findings offer promising directions for future research, but they also remind us that scientific progress requires careful investigation.
For women navigating PCOS and fertility challenges, understanding these developments can support more informed conversations with healthcare professionals.
Because reproductive wellbeing begins with understanding the whole body.
多囊卵巢综合征（PCOS）与生育力：最新研究能否为备孕带来新希望？
对于患有多囊卵巢综合征（PCOS）的女性来说，备孕有时并不是一件容易的事。
月经不规律、排卵障碍、激素水平变化以及胰岛素抵抗，都可能对女性的生殖健康产生影响。
近年来，越来越多的科学研究发现，代谢健康与女性生育力之间存在着密切联系。
2026年10月发表的两项研究，再次将这一话题带入公众视野。研究人员开始进一步探索，原本用于糖尿病及体重管理的GLP-1类药物，是否可能对PCOS女性的生殖健康产生积极影响。
这些发现为理解女性生育力提供了新的研究方向。
一、最新研究：GLP-1类药物可能影响PCOS女性的自然受孕机会
2026年10月15日，发表于《欧洲妇产科与生殖生物学杂志》（European Journal of Obstetrics & Gynecology and Reproductive Biology）的一项系统综述及荟萃分析，探讨了GLP-1受体激动剂对PCOS女性妊娠结局的影响。
GLP-1类药物包括利拉鲁肽（Liraglutide）、司美格鲁肽（Semaglutide）等，主要用于改善血糖调节及体重管理。
研究人员分析了3项随机对照试验，共涉及252名参与者。
研究结果显示：
- 与单独使用二甲双胍相比，GLP-1类治疗可能提高PCOS女性的自然受孕机会。
- 在总体妊娠率及试管婴儿（IVF）妊娠结局方面，尚未发现具有统计学意义的改善。
- 目前研究样本量有限，仍需要更大规模的临床试验进一步验证。
这项研究提示，改善代谢功能可能是未来PCOS生育管理值得探索的方向之一。
但需要强调的是，GLP-1类药物目前并非已确立的促孕治疗方案，也不能将初步研究结果理解为能够直接提高生育成功率。
二、为什么代谢健康会影响女性生育力？
PCOS并不仅仅是卵巢的问题。
它是一种涉及内分泌、代谢及生殖系统的复杂疾病。
其中，胰岛素抵抗是许多PCOS女性面临的重要问题。
当身体细胞对胰岛素的反应降低时，机体可能需要分泌更多胰岛素来维持正常血糖水平。
而较高的胰岛素水平可能进一步促进雄激素分泌，干扰正常的卵泡发育与排卵过程。
这种变化可能表现为：
- 月经周期不规律
- 排卵频率减少
- 雄激素水平升高
- 体重管理困难
- 自然受孕机会受到影响
因此，在PCOS的生殖健康管理中，关注血糖调节、营养状态、生活方式及整体代谢健康，具有重要意义。
值得注意的是，并非所有PCOS女性都存在超重或明显的胰岛素抵抗，每个人的情况都需要个体化评估。
三、另一项研究：孕前代谢管理与妊娠结局之间的联系
2026年10月10日，《临床内分泌与代谢杂志》（The Journal of Clinical Endocrinology & Metabolism）发表了另一项相关研究。
研究人员通过观察性数据分析，比较了孕前接受GLP-1类及相关治疗的PCOS女性，与接受二甲双胍治疗女性的妊娠及代谢相关结局。
研究涉及两组各48,126名女性。
结果发现，孕前接受相关治疗与部分不良妊娠结局风险降低存在关联。
然而，这是一项观察性研究，因此无法证明药物本身直接导致了这些改善。
研究也不能证明GLP-1类药物在妊娠期间使用是安全的。
这项研究真正值得关注的，是孕前代谢健康可能与后续妊娠结局存在的重要联系。
对于准备怀孕的女性来说，孕前健康管理不仅仅是关注排卵和受孕，也包括对整体身体状态的了解与评估。
四、对于正在备孕的PCOS女性，这意味着什么？
随着生殖医学的发展，科学家逐渐认识到，女性生育力受到多种生理因素的共同影响。
对于PCOS女性而言，备孕管理可以从多个方面入手：
1. 了解自己的排卵情况
通过月经周期记录及必要的医学检查，了解是否存在排卵不规律或排卵障碍。
2. 关注代谢健康
根据个人情况，在医生指导下评估血糖、胰岛素抵抗及其他相关代谢指标。
3. 重视均衡营养与生活方式
规律运动、充足睡眠及均衡饮食，有助于支持整体代谢健康。
4. 提前进行孕前咨询
如果正在使用GLP-1类药物，应在计划怀孕前咨询医生，确认适当的停药时间及后续管理方案。
5. 寻求个体化的生育建议
对于存在持续排卵障碍或备孕困难的女性，应及时咨询妇科或生殖医学专科医生。
这些措施的核心并不是追求单一的“快速改善”，而是通过科学评估，更全面地了解自己的生殖健康。
五、SHAWKEA：以科学视角关注女性生殖健康
在SHAWKEA，我们始终相信，女性生殖健康需要从更全面的角度理解。
从营养状态、代谢功能，到激素调节与细胞生理过程，身体的不同系统之间存在着复杂而紧密的联系。
近年来，关于PCOS、胰岛素抵抗及生育力的研究不断发展，也进一步体现了科学探索的重要性。
SHAWKEA长期关注女性健康与营养科学，致力于探索植物来源成分及其相关生物学研究，为女性生殖健康领域提供更多科学交流与知识分享。
需要说明的是，本文介绍的GLP-1相关研究并未针对SHAWKEA T-1或其成分开展试验，因此不能据此推断SHAWKEA产品具有治疗PCOS、改善排卵或提高妊娠率的效果。
我们相信，真正有价值的健康理念，应当建立在严谨研究、透明信息与科学认知之上。
六、未来展望：从关注卵巢，到理解整体生殖健康
随着研究不断深入，生殖医学正在逐步拓展对女性生育力的认识。
卵巢功能、激素平衡、代谢状态以及孕前健康，可能共同影响女性的生殖过程。
2026年10月的最新研究为PCOS与生育力领域提供了值得继续探索的科学线索，但距离形成新的临床治疗标准，仍需要更多高质量证据。
对于正在备孕的女性而言，了解这些科学进展，有助于与专业医疗人员进行更充分的沟通，并作出适合自己的健康选择。
关注生育力，不只是关注怀孕的结果，更是从科学角度理解女性身体的整体健康。
Scientific References
-
Kar E, et al. (2026). The effect of glucagon-like peptide-1 receptor agonists versus metformin on pregnancy rates in women with polycystic ovary syndrome: a systematic review and meta-analysis of randomized trials. European Journal of Obstetrics & Gynecology and Reproductive Biology. https://doi.org/10.1016/j.ejogrb.2026.115499
-
Henney AE, et al. (2026). Preconception incretin therapy reduces pregnancy and cardiometabolic outcomes in polycystic ovary syndrome. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgag423